Alpha Tau Medical Statistics
Total Valuation
DRTS has a market cap or net worth of $1.22 billion. The enterprise value is $1.15 billion.
| Market Cap | 1.22B |
| Enterprise Value | 1.15B |
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026, after market close.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DRTS has 90.33 million shares outstanding. The number of shares has increased by 21.80% in one year.
| Current Share Class | 90.33M |
| Shares Outstanding | 90.33M |
| Shares Change (YoY) | +21.80% |
| Shares Change (QoQ) | +4.11% |
| Owned by Insiders (%) | 15.24% |
| Owned by Institutions (%) | 6.00% |
| Float | 62.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 476.23 |
| PB Ratio | 17.09 |
| P/TBV Ratio | 17.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.79, with a Debt / Equity ratio of 0.21.
| Current Ratio | 7.79 |
| Quick Ratio | 7.31 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.64 |
Financial Efficiency
Return on equity (ROE) is -90.51% and return on invested capital (ROIC) is -37.99%.
| Return on Equity (ROE) | -90.51% |
| Return on Assets (ROA) | -30.50% |
| Return on Invested Capital (ROIC) | -37.99% |
| Return on Capital Employed (ROCE) | -47.08% |
| Weighted Average Cost of Capital (WACC) | 11.28% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$470,041 |
| Employee Count | 121 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, DRTS has paid $11,000 in taxes.
| Income Tax | 11,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +300.89% in the last 52 weeks. The beta is 1.18, so DRTS's price volatility has been higher than the market average.
| Beta (5Y) | 1.18 |
| 52-Week Price Change | +300.89% |
| 50-Day Moving Average | 11.53 |
| 200-Day Moving Average | 7.79 |
| Relative Strength Index (RSI) | 61.44 |
| Average Volume (20 Days) | 549,983 |
Short Selling Information
The latest short interest is 2.98 million, so 3.30% of the outstanding shares have been sold short.
| Short Interest | 2.98M |
| Short Previous Month | 2.21M |
| Short % of Shares Out | 3.30% |
| Short % of Float | 4.80% |
| Short Ratio (days to cover) | 3.70 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -46.29M |
| Pretax Income | -56.86M |
| Net Income | -56.88M |
| EBITDA | -46.29M |
| EBIT | -46.29M |
| Earnings Per Share (EPS) | -$0.67 |
Balance Sheet
The company has $76.42 million in cash and $14.34 million in debt, with a net cash position of $62.08 million or $0.69 per share.
| Cash & Cash Equivalents | 76.42M |
| Total Debt | 14.34M |
| Net Cash | 62.08M |
| Net Cash Per Share | $0.69 |
| Equity (Book Value) | 69.35M |
| Book Value Per Share | 0.77 |
| Working Capital | 70.90M |
Cash Flow
In the last 12 months, operating cash flow was -$26.68 million and capital expenditures -$6.08 million, giving a free cash flow of -$32.76 million.
| Operating Cash Flow | -26.68M |
| Capital Expenditures | -6.08M |
| Depreciation & Amortization | 1.26M |
| Net Borrowing | n/a |
| Free Cash Flow | -32.76M |
| FCF Per Share | -$0.36 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DRTS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.80% |
| Shareholder Yield | -21.80% |
| Earnings Yield | -4.69% |
| FCF Yield | -2.70% |
Analyst Forecast
The average price target for DRTS is $14.20, which is 5.50% higher than the current price. The consensus rating is "Buy".
| Price Target | $14.20 |
| Price Target Difference | 5.50% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |